The Quality of Antimalarials - A Study in Selected African Countries - EDM Research Series No. 030
(2003; 67 pages) View the PDF document
Table of Contents
View the documentAuthors
View the documentCountry Research Team Leaders
View the documentLaboratory Support
View the documentAcknowledgements
View the documentAcronyms
View the documentExecutive summary
View the document1. Background
Open this folder and view contents2. Methodology
View the document3. Results
Open this folder and view contents4. Discussion
Close this folder5. Conclusions and recommendations
View the document5.1 Conclusions
View the document5.2 Need for further studies
View the document5.3 Recommendations for further studies
View the document5.4 Recommendations for quality and bio-equivalence surveillance
View the documentReferences
Open this folder and view contentsTables
Open this folder and view contentsAnnexes
View the documentOther documents in the EDM Research Series
View the documentEDM Research Series No. 30

5.1 Conclusions

Significant problems of substandard products exist within the drug distribution chains. Percentage failure of samples based on ingredient content ranging from 20% to 67% for CQT and 5% to 28% for SPT, and in dissolution failures ranging from 5% to 33% for CQT and 75% to 100% for SPT, cannot be ignored. In view of the potential danger that substandard antimalarials could already be posing in the fight against malaria, an intervention plan should be developed immediately. This could involve setting up quality surveillance systems within drug regulatory authorities in the region and supporting manufacturers to improve GMP compliance.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018